|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
FR2459619B1
(fr)
|
1979-06-26 |
1983-07-29 |
Agronomique Inst Nat Rech |
Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
|
|
US4350156A
(en)
|
1980-05-29 |
1982-09-21 |
Japan Foundation For Artificial Organs |
Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
|
|
US4455256A
(en)
|
1981-05-05 |
1984-06-19 |
The Regents Of The University Of California |
Bone morphogenetic protein
|
|
WO1994021316A1
(en)
|
1993-03-24 |
1994-09-29 |
Owen Mumford Limited |
Improvements relating to injection devices
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
US5631347A
(en)
|
1995-06-07 |
1997-05-20 |
Eli Lilly And Company |
Reducing gelation of a fatty acid-acylated protein
|
|
DE19543737A1
(de)
|
1995-11-24 |
1997-05-28 |
Hoechst Ag |
Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
IL140592A0
(en)
|
1998-07-23 |
2002-02-10 |
Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
EP2090583B1
(en)
|
1998-09-25 |
2011-07-13 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
WO2000020010A1
(en)
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
EP1128839A4
(en)
|
1998-11-12 |
2002-10-09 |
Yeda Res & Dev |
PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
|
|
ATE329608T1
(de)
|
2000-02-18 |
2006-07-15 |
Yeda Res & Dev |
Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
|
|
ZA200206457B
(en)
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
JP2003535118A
(ja)
|
2000-06-05 |
2003-11-25 |
テバ ファーマシューティカル インダストリーズ リミティド |
中枢神経系障害の治療におけるグラチラマーアセテート（共重合体１）の使用
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
DE10158009A1
(de)
*
|
2001-11-21 |
2003-05-28 |
Begerow E Gmbh & Co |
Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen
|
|
MXPA04005433A
(es)
|
2001-12-04 |
2004-10-11 |
Teva Pharma |
Proceso para la medicion de la potencia de acetato de glatiramero.
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
US7777006B2
(en)
|
2002-12-31 |
2010-08-17 |
Csl Behring L.L.C. |
Method for purification of alpha-1-antitrypsin
|
|
PT1592384E
(pt)
|
2003-01-21 |
2013-01-28 |
Yeda Res & Dev |
Cop-1 para o tratamento de doenças inflamatórias do intestino
|
|
CA2518079A1
(en)
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
HRP20140524T1
(hr)
|
2003-05-14 |
2014-12-19 |
Teva Pharmaceutical Industries Ltd. |
Kombinacijska terapija glatiramer acetatom i mitoksantronom za lijeäśenje multiple skleroze
|
|
KR101137785B1
(ko)
|
2003-07-18 |
2012-04-25 |
백스터 인터내셔널 인코포레이티드 |
제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
|
|
EA200600877A1
(ru)
|
2003-10-31 |
2006-12-29 |
Тева Фармасьютикал Индастриз, Лтд. |
Наночастицы для доставки лекарств
|
|
EP1701971A2
(en)
|
2003-12-31 |
2006-09-20 |
F.Hoffmann-La Roche Ag |
Peptide synthesis using decanting filter
|
|
CA2558380A1
(en)
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
CA2579038A1
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
KR101317131B1
(ko)
|
2004-09-09 |
2013-10-10 |
테바 파마슈티컬 인더스트리즈 리미티드 |
정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
WO2006050122A1
(en)
|
2004-10-29 |
2006-05-11 |
Sandoz Ag |
Processes for preparing glatiramer
|
|
WO2006083608A1
(en)
|
2005-02-02 |
2006-08-10 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
US20080261894A1
(en)
|
2005-02-17 |
2008-10-23 |
Rivka Kreitman |
Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
CA2606194A1
(en)
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
WO2007030573A2
(en)
|
2005-09-09 |
2007-03-15 |
Yeda Research And Development Co. Ltd. |
Polypeptides useful for molecular weight determinations
|
|
WO2007081975A2
(en)
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US20080118553A1
(en)
|
2006-06-12 |
2008-05-22 |
Anton Frenkel |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
ATE452140T1
(de)
|
2006-07-05 |
2010-01-15 |
Momenta Pharmaceuticals Inc |
Verbessertes verfahren zur herstellung von copolymer-1
|
|
CN100569282C
(zh)
|
2006-10-13 |
2009-12-16 |
俞嘉林 |
注射用骨肽冻干剂及其制备方法
|
|
ES2477232T5
(es)
|
2007-06-21 |
2017-11-23 |
Momenta Pharmaceuticals, Inc. |
Análisis de copolímeros
|
|
EP2173766A1
(en)
|
2007-07-31 |
2010-04-14 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
US20090149541A1
(en)
|
2007-11-28 |
2009-06-11 |
Yafit Stark |
Method of delaying the onset of clinically definite multiple sclerosis
|
|
WO2009139924A2
(en)
|
2008-05-14 |
2009-11-19 |
Otonomy, Inc. |
Controlled release corticosteroid compositions and methods for the treatment of otic disorders
|
|
US8323685B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
CA2697570C
(en)
*
|
2009-07-15 |
2011-11-01 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
HUE031282T2
(hu)
|
2009-08-20 |
2017-06-28 |
Yeda Res & Dev |
Alacsony gyakoriságú glatiramer acetát terápia
|
|
ITMI20092069A1
(it)
|
2009-11-25 |
2011-05-26 |
Biofer Spa |
Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro.
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
NZ703122A
(en)
|
2010-10-11 |
2016-06-24 |
Teva Pharma |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
WO2012123959A2
(en)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
|
US8575198B1
(en)
*
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
KR20140101730A
(ko)
|
2011-10-10 |
2014-08-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
|
|
ES2706065T3
(es)
*
|
2012-07-06 |
2019-03-27 |
3 D Matrix Ltd |
Proceso de llenado-acabado para soluciones de péptidos
|
|
HK1213830A1
(zh)
|
2012-10-10 |
2016-07-15 |
Teva Pharmaceutical Industries Ltd. |
用於预测醋酸格拉替雷临床反应的生物标志物
|
|
EA201591251A1
(ru)
|
2013-01-04 |
2016-05-31 |
Тева Фармасьютикал Индастриз Лтд. |
Характеризация лекарственного продукта, родственного ацетату глатирамера
|
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
|
EA201591687A1
(ru)
|
2013-03-12 |
2016-07-29 |
Тева Фармасьютикал Индастриз Лтд. |
Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
|
|
CN103169670B
(zh)
*
|
2013-03-22 |
2016-07-06 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷微球及其制备方法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|